| P/E (FY) | — | Sales (TTM) | $254.9M |
| Earnings (TTM) | -$103.5M | ROE | −26.29% |
| Net Margin | −40.36% | ROIC | −64.69% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 12.24% |
Schrodinger, Inc. develops a physics-based computational platform for discovering molecules used in drug development and materials applications, with operations across the United States, Asia-Pacific, Europe, the Middle East, Africa, and internationally. It operates Software and Drug Discovery segments. Software is sold to life sciences and materials science industries, while Drug Discovery builds a portfolio of preclinical and clinical programs internally and through collaborations, including with Novartis Pharma AG.
| Market Cap | $1.12B | Trading Days | 1621 |
| 52W High | 23.02 |
| 52W Low | 10.95 |
| % Off High | −33.58% |
| YTD | −14.49% | 1Y | −31.71% |
| 3Y | −68.87% | 5Y | −78.19% |
| Since incept. (ann.) | −9.24% |
Software 78% · Drug Discovery 22%
| Ann. Volatility (1Y) | 51.24% | Ann. Volatility (3Y) | 60.81% |
| Sharpe (1Y) | −0.51 | Sharpe (3Y) | −0.33 |
| Max Drawdown (1Y) | −50.84% | Max Drawdown (3Y) | −78.85% |
| Beta (3Y, vs SPY) | 2.17 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CRVS | Corvus Pharmaceuticals, Inc. | $1.12B | — |
| WVE | Wave Life Sciences Ltd. | $1.13B | — |
| SPTX | Seaport Therapeutics, Inc. | $1.10B | — |
| SVRA | Savara Inc | $1.09B | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $1.16B | 20.8 |
| FBRX | Forte Biosciences, Inc. | $1.06B | — |
| CBIO | CRESCENT BIOPHARMA, INC. | $1.06B | — |
| PCRX | Pacira BioSciences, Inc. | $1.05B | 167.6 |
| MNKD | MANNKIND CORP | $1.21B | 195.5 |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $1.04B | — |
| AVLN | Avalyn Pharma Inc. | $1.22B | — |
| AVTX | Avalo Therapeutics, Inc. | $1.03B | — |
